精(jing)華制藥集(ji)團股(gu)份(fen)有限公(gong)司(si)是(shi)由南(nan)通(tong)產控(kong)集(ji)團控(kong)股(gu)、國資(zi)(zi)(zi)監管的地方國有控(kong)股(gu)企業,由原(yuan)南(nan)通(tong)中(zhong)誠制藥有限公(gong)司(si)(南(nan)通(tong)中(zhong)藥廠(chang))變更、重組南(nan)通(tong)制藥總廠(chang)(南(nan)通(tong)制藥廠(chang)、南(nan)通(tong)制藥二廠(chang))優(you)質資(zi)(zi)(zi)源,并吸(xi)收民營(ying)資(zi)(zi)(zi)本南(nan)通(tong)綜藝(yi)投資(zi)(zi)(zi)有限公(gong)司(si)以及(ji)自然人投資(zi)(zi)(zi)設立。2010年2月在(zai)深交所(suo)中(zhong)小板掛(gua)牌上市,股(gu)票簡稱:精(jing)華制藥,證券代號(hao):002349。
公(gong)(gong)司(si)已有60多(duo)年的制(zhi)(zhi)藥(yao)歷史(shi),是一家(jia)綜合性的現代化GMP制(zhi)(zhi)藥(yao)有限公(gong)(gong)司(si)。目前(qian)擁有7個子公(gong)(gong)司(si),是一家(jia)集中藥(yao)制(zhi)(zhi)劑(ji)(ji)、中藥(yao)飲(yin)片(pian)(pian)、西(xi)藥(yao)制(zhi)(zhi)劑(ji)(ji)、醫藥(yao)中間(jian)(jian)體、化學原料藥(yao)、生(sheng)物制(zhi)(zhi)藥(yao)、保健(jian)品(pin)(pin)等生(sheng)產(chan)、銷售和研發的綜合型制(zhi)(zhi)藥(yao)企業(ye)集團。公(gong)(gong)司(si)有中西(xi)藥(yao)品(pin)(pin)種(zhong)(zhong)200余(yu)種(zhong)(zhong),中藥(yao)產(chan)品(pin)(pin)主(zhu)要有享譽海內外(wai)的經典名藥(yao)“五朵金花(hua)”王氏保赤丸、季(ji)德(de)勝蛇藥(yao)片(pian)(pian)、正(zheng)柴胡飲(yin)顆(ke)粒、大柴胡顆(ke)粒、金蕎(qiao)麥膠囊,以及(ji)固(gu)本咳喘(chuan)片(pian)(pian)、暈可平糖漿、精血補片(pian)(pian)等,這些中藥(yao)品(pin)(pin)種(zhong)(zhong)都(dou)有著廣(guang)泛(fan)的歷史(shi)背(bei)景(jing)及(ji)深厚的文化底(di)蘊,其中季(ji)德(de)勝蛇藥(yao)片(pian)(pian)、王氏保赤丸制(zhi)(zhi)作(zuo)技藝均被(bei)列(lie)入(ru)國家(jia)非物質文化遺產(chan)。原料藥(yao)產(chan)品(pin)(pin)主(zhu)要有苯巴比妥、撲米(mi)酮、氟尿嘧啶(ding)、保泰松、氟胞(bao)嘧啶(ding)、吡羅昔康(kang)、替諾昔康(kang)、丙硫氧嘧啶(ding)、非那西(xi)丁、雙嘧達莫以及(ji)其它(ta)醫藥(yao)中間(jian)(jian)體等。其中已有10個品(pin)(pin)種(zhong)(zhong)通(tong)(tong)過國家(jia)GMP認(ren)證,5個品(pin)(pin)種(zhong)(zhong)通(tong)(tong)過歐盟CEP認(ren)證,2個品(pin)(pin)種(zhong)(zhong)通(tong)(tong)過澳(ao)大利(li)亞GMP認(ren)證,3個品(pin)(pin)種(zhong)(zhong)通(tong)(tong)過墨西(xi)哥官方認(ren)證,4個品(pin)(pin)種(zhong)(zhong)獲(huo)得美國DMF注冊文件(jian) ,1個品(pin)(pin)種(zhong)(zhong)獲(huo)得美國VMF注冊文件(jian),并已通(tong)(tong)過美國FDA現場核查。
精(jing)華制藥(yao)(yao)(yao)將會以“成為(wei)以傳(chuan)(chuan)(chuan)世(shi)中(zhong)藥(yao)(yao)(yao)為(wei)核(he)心特色(se)的全國(guo)現(xian)代醫藥(yao)(yao)(yao)企業(ye)”為(wei)戰略(lve)目標(biao),深(shen)入貫徹(che)《關于(yu)促(cu)進中(zhong)醫藥(yao)(yao)(yao)傳(chuan)(chuan)(chuan)承創(chuang)新發(fa)展的意見》精(jing)神,聚(ju)焦(jiao)“五(wu)朵(duo)金花”傳(chuan)(chuan)(chuan)世(shi)中(zhong)藥(yao)(yao)(yao)主業(ye)為(wei)主,特色(se)化學原料藥(yao)(yao)(yao)及化學制劑為(wei)輔(fu)的“雙輪(lun)驅動”的發(fa)展戰略(lve),依托(tuo)品(pin)牌(pai)力和(he)渠道力,致力于(yu)成為(wei)以傳(chuan)(chuan)(chuan)世(shi)中(zhong)藥(yao)(yao)(yao)為(wei)核(he)心特色(se)的全國(guo)現(xian)代醫藥(yao)(yao)(yao)企業(ye)。